Stocktoria
Taysha Gene Therapies, Inc. TSHA
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-09-24
Taysha Gene Therapies, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M | — | — |
| R&D expense | $86.4M | $66.0M | $56.8M | $91.2M | $131.9M | $31.9M |
| Operating income | -$110.5M | -$91.5M | -$72.4M | -$162.4M | -$173.3M | -$43.0M |
| Interest expense | — | — | $5.0M | $3.8M | $1.4M | $28,000 |
| Income tax | $0 | $0 | $0 | $0 | — | $0 |
| Net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M | -$174.5M | -$60.0M |
| EPS (diluted) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | — |
| Operating cash flow | -$93.1M | -$81.2M | -$73.0M | -$88.4M | -$117.0M | -$30.7M |
| Free cash flow | -$93.8M | -$81.6M | -$76.9M | -$109.0M | -$132.3M | -$30.8M |
| Cash & equivalents | $319.8M | $139.0M | $143.9M | $87.9M | $149.1M | $251.3M |
| Total assets | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M | $258.9M |
| Total liabilities | $96.4M | $88.8M | $97.8M | $125.3M | $118.6M | $7.6M |
| Shareholders' equity | $246.9M | $71.5M | $74.9M | $949,000 | $95.4M | $251.3M |
Growth · year-over-year · Revenue CAGR 57.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +17.3% | -46.1% | +517.5% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.